Konstantin Byrgazov
Konstantin Byrgazov
Verified email at
Cited by
Cited by
Selective translation of leaderless mRNAs by specialized ribosomes generated by MazF in Escherichia coli
O Vesper, S Amitai, M Belitsky, K Byrgazov, AC Kaberdina, ...
Cell 147 (1), 147-157, 2011
Ribosome heterogeneity: another level of complexity in bacterial translation regulation
K Byrgazov, O Vesper, I Moll
Current opinion in microbiology 16 (2), 133-139, 2013
Structural basis for the interaction of protein S1 with the Escherichia coli ribosome
K Byrgazov, I Grishkovskaya, S Arenz, N Coudevylle, H Temmel, ...
Nucleic Acids Research 43 (1), 661-673, 2015
Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia
G Heller, T Topakian, C Altenberger, S Cerny-Reiterer, S Herndlhofer, ...
Leukemia 30 (9), 1861-1868, 2016
The MazF-regulon: a toolbox for the post-transcriptional stress response in Escherichia coli
M Sauert, MT Wolfinger, O Vesper, C Müller, K Byrgazov, I Moll
Nucleic Acids Research 44 (14), 6660-6675, 2016
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia
KV Gleixner, M Schneeweiss, G Eisenwort, D Berger, H Herrmann, K Blatt, ...
Haematologica 102 (9), 1519, 2017
Direct interaction of the N-terminal domain of ribosomal protein S1 with protein S2 in Escherichia coli
K Byrgazov, S Manoharadas, AC Kaberdina, O Vesper, I Moll
PLoS One 7 (3), e32702, 2012
Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1T315I-compound mutations
KV Gleixner, Y Filik, D Berger, C Schewzik, G Stefanzl, I Sadovnik, ...
American journal of cancer research 11 (9), 4470, 2021
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
K Byrgazov, CB Lucini, P Valent, O Hantschel, T Lion
Haematologica 103 (1), e10, 2018
Block synthesis of blood group tetrasaccharides B (types 1, 3 and 4)
EY Korchagina, IM Ryzhov, KA Byrgazov, IS Popova, SN Pokrovsky, ...
Mendeleev Communications 19 (3), 152-154, 2009
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML
M Schneeweiss-Gleixner, K Byrgazov, G Stefanzl, D Berger, G Eisenwort, ...
EBioMedicine 50, 111-121, 2019
NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors
K Byrgazov, R Kastner, M Gorna, G Hoermann, M Koenig, CB Lucini, ...
Leukemia 31 (1), 237-240, 2017
Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors
K Byrgazov, CB Lucini, B Berkowitsch, M Koenig, OA Haas, G Hoermann, ...
Oncotarget 7 (47), 78083, 2016
Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
K Byrgazov, C Anderson, B Salzer, E Bozsaky, R Larsson, J Gullbo, ...
Therapeutic Advances in Medical Oncology 12, 1758835920937891, 2020
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
K Byrgazov, M Kraus, A Besse, A Slipicevic, F Lehmann, C Driessen, ...
Leukemia research 101, 106499, 2021
Novel peptide-drug conjugate melflufen efficiently eradicates bortezomib-resistant multiple myeloma cells including tumor-initiating myeloma progenitor cells
K Byrgazov, A Besse, M Kraus, A Slipicevic, F Lehmann, C Driessen, ...
Hemasphere 5 (7), 2021
A novel fusion gene NDEL1-Pdgfrb in a patient with JMML with a new variant of TKI-resistant mutation in the kinase domain of PDGFRβ
K Byrgazov, R Kastner, M Dworzak, G Hoermann, OA Haas, R Ulreich, ...
Blood 124 (21), 613, 2014
A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML
KV Gleixner, I Sadovnik, M Schneeweiss, G Eisenwort, K Byrgazov, ...
Leukemia research 78, 36-44, 2019
Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes
K Byrgazov, T Lind, AJ Rasmusson, C Andersson, A Slipicevic, ...
Bone Reports 15, 101098, 2021
Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml
KV Gleixner, MA Schneeweiss, H Herrmann, K Blatt, D Berger, ...
Blood 128 (22), 4241, 2016
The system can't perform the operation now. Try again later.
Articles 1–20